L17 Ph2 48 wk trial dual neutralization of IL‑17A and IL‑17F w/bezilkumab in PsA: at wk 12 ACR 50 And PASI and maintained at wk 48. Serious AEs around 4% at wks24&48, not dose related; most common nasopharyngitis. Oral candidiasis 10/206 (4.9%) at wk48 in BZK. #acr18 @rheumnow